European Journal of Cancer · 2023 · 15 citations · 20 references
MedicineOncologyPharmacologyBreast OncologyChemotherapyMolecular OncologyBreast Cancer OncologyBreast Cancer PharmacotherapyCancer PharmacogenomicsCancer ProgressionMetastatic Breast CancerTargeted TherapyBrca MutationsBrca1 InactivationBreast Cancer ChemotherapyParp InhibitionParp Inhibitor ResistanceParp Inhibitor SensitivityPathogenic Germline VariantsPlatinum-based Regimens
20
Olaparib for Metastatic Breast Cancer in Patients with a Germline <i>BRCA</i> Mutation
Mark E. Robson, Seock‐Ah Im, Elżbieta Senkus et al. · New England Journal of Medicine · 2017 · 3.2K citations · Full text
Medicine, Oncology, Pharmacology +16
Éric Pujade-Lauraine, Jonathan A. Ledermann, Frédèric Selle et al. · The Lancet Oncology · 2017 · 1.9K citations
Pharmacy, Oncology, Pharmacotherapy +14
Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial
Andrew Tutt, Holly Tovey, Maggie C.U. Cheang et al. · Nature Medicine · 2018 · 903 citations · Full text
Medicine, Oncology, Pharmacology +11